New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
09:06 EDTLGNDLigand price target raised to $91 from $78 at Summer Street
Summer Street raised its price target for Ligand shares to $91 following the company's Q4 results and 2014 outlook. It keeps a Buy rating on the stock.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
09:01 EDTLGNDLigand enters into OmniAb platform license pact with Tizona
Ligand Pharmaceuticals announced it has entered into a worldwide license agreement with Tizona Therapeutics, Inc. Under the license, Tizona will use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use